Merck Deal History & Licensing Activity
Merck is a large pharma headquartered in US. Over the past three years, Merck has been involved in 18 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
6
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
Merck Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Merck in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| SPR2015 | SciBrunch Therapeutics | Small Molecules | Preclinical | license | Sep 28, 2026 |
| [212Pb]PSV359 | Perspective Therapeutics | Radiopharmaceuticals | Phase 1 | collaboration | Sep 14, 2026 |
| antibody discovery collaboration | Infinimmune | Antibodies | Discovery | collaboration | Mar 31, 2026 |
| TERN-701 | Merck & Co. | Small Molecules | Phase 1 | acquisition | Mar 25, 2026 |
| Undisclosed | Merck & Co. | Other | Discovery | collaboration | Mar 24, 2026 |
| Cidara Therapeutics (corporate acquisition; includes CD388/rezafungin and DFC platform) | Cidara Therapeutics | ADC | Phase 3 | acquisition | Nov 14, 2025 |
Merck Pipeline Focus
Therapeutic areas and modalities where Merck is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Merck Strategic Signals
Key indicators of Merck's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Merck Clinical Pipeline
Merck has 50 active clinical trials across 7 development phases.
1
Unknown
2
Phase 4
7
Phase 1
4
Phase 1/2
16
Phase 2
5
Phase 2/3
15
Phase 3
See How Your Asset Matches Merck's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Radiopharmaceuticals Benchmarks
Upfront, milestone, and royalty benchmarks for radiopharmaceuticals deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Merck Licensing & Deal Activity
Merck is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 18 deals over the past three years, Merck ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Merck include Solid Tumors (18 deals and trials), Oncology (13 deals and trials), Hematological Malignancies (6 deals and trials), and Cardiovascular (5 deals and trials). In terms of modality, Merck has shown particular interest in small molecules, radiopharmaceuticals, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Merck and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Merck's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.